C4 Therapeutics, Inc. (CCCC) — Analyst outlook / Analyst consensus target is. Based on 14 analyst ratings, the consensus is bullish — 10 Buy, 3 Hold, 1 Sell.
The consensus price target is $7.00, representing an upside of 153.6% from the current price $2.76.
Analysts estimate Earnings Per Share (EPS) of $-1.49 and revenue of $0.04B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.52 vs est $-1.49 (missed -2%). 2025: actual $-1.27 vs est $-1.41 (beat +9.7%). Analyst accuracy: 94%.
CCCC Stock — 12-Month Price Forecast
$7.00
▲ +153.62% Upside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for C4 Therapeutics, Inc., the price target is $7.00.
The average price target represents a +153.62% change from the last price of $2.76.
CCCC Analyst Ratings
Buy
Based on 14 analysts giving stock ratings to C4 Therapeutics, Inc. in the past 3 months
EPS Estimates — CCCC
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.52
vs Est –$1.49
▼ 1.9% off
2025
Actual –$1.27
vs Est –$1.41
▲ 10.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — CCCC
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.036B
vs Est $0.036B
▼ 0.6% off
2025
Actual $0.036B
vs Est $0.030B
▲ 15.6% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
